HER2-Positive Breast Cancer: New Findings, Expanded Options, and an Evolving Treatment Paradigm

Learn from the experts how to leverage new and established HER2-targeting agents for optimal management of HER2+ early and metastatic breast cancer with these downloadable slides and on-demand Webcast.

Share

Program Content

Activities

HER2+ BC: Webcast
HER2-Positive Breast Cancer: New Findings, Expanded Options, and an Evolving Treatment Paradigm
Congratulations: You achieved a completion on 04/09/2022

Activities

HER2+ EBC Guidance
Expert Guidance on the Evolving Therapeutic Landscape for HER2-Positive Early-Stage Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 30, 2020

Expires: June 29, 2021

HER2+ MBC Targeted Tx
HER2-Positive Metastatic Breast Cancer: Current Status and Promising Agents on the Horizon
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 30, 2020

Expires: June 29, 2021

<i>EP</i>: HER2+ EBC and MBC
ExpressPoints: An Evolving Treatment Paradigm in HER2-Positive Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 08, 2020

Expires: July 07, 2021

Faculty

cover img faculity

Neelima Denduluri, MD, FASCO

Clinical Assistant Professor
Georgetown University
Washington, DC
Medical Oncologist
Virginia Cancer Specialists
Co-Director, Virginia Cancer Specialists Research Program
Associate Chair, US Oncology Breast Cancer Research Committee
Arlington, Virginia

cover img faculity

Lee Schwartzberg, MD

Professor of Medicine
Chief
Division of Hematology and Oncology
University of Tennessee Health Science Center
Memphis, Tennessee
Executive Director
West Cancer Center
Germantown, Tennessee

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Puma Biotechnology, Inc.

Seagen